SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

The FDAs accelerated approval of Inovios competing RRP treatment, Voceryq, has raised concerns about pressure on Precigens PAPZIMEOS sales. Traders debate the competitive threat against PAPZIMEOSs first-mover position and full approval, while some question Inovios ability to commercialize its drug and note its confirmatory-study requirement.

Compound (COMP) is a cryptocurrency and operates on the Ethereum platform. Compound has a current supply of 10,000,000 with 9,999,999.99995246 in circulation. The last known price of Compound is 20.49527411 USD and is down -2.02 over the last 24 hours. It is currently trading on 652 active market(s) with $25,001,434.49 traded over the last 24 hours. More information can be found at https://www.compound.xyz/.

Compound

Compounds institutional-market rollout and broader institutional push are the main focus, with traders linking the effort to potential growth in DeFi and tokenized assets. Some see it as a catalyst for COMP, while others remain frustrated that the token has lagged the wider crypto market.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

AstraZenecas reported Baxfendy sales have traders questioning how quickly the new aldosterone-inhibitor class can gain coverage and commercial traction, weighing on expectations for Mineralys planned launch. Some see the early sales as a normal reimbursement ramp for a chronic treatment, while others worry that a slow launch and competition could constrain lorundrostats sales potential.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445403. The last known price of Zebec Network is 0.00204055 USD and is down -0.09 over the last 24 hours. It is currently trading on 133 active market(s) with $10,537,951.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Discussion centers on Zebecs reported payroll and payments integrationsincluding MoneyGram/Stellar, European deployments, and Robinhood Chain supportwhich traders see as potential drivers of adoption and ZBCN demand. Others question whether these partnerships will translate into meaningful token use, noting the coins weak or uneven price performance; some rumored connections remain unconfirmed.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIMs raised full-year outlook amid strong shipping demand and elevated freight rates is fueling expectations for stronger profits and dividends. Traders are also debating the uncertain Hapag-Lloyd takeover, with Israeli regulatory opposition raising the possibility the deal could be delayed or fail.

dogwifhat (WIF) is a cryptocurrency and operates on the Solana platform. dogwifhat has a current supply of 998,836,666.706979. The last known price of dogwifhat is 0.1786325 USD and is up 7.56 over the last 24 hours. It is currently trading on 831 active market(s) with $51,931,928.88 traded over the last 24 hours. More information can be found at https://dogwifhat.us/.

dogwifhat

WIF is drawing attention for its prolonged sideways-to-lower trading and repeated selloffs that erase brief gains, with traders complaining about barcoding and weak performance. Some view the depressed range as an accumulation opportunity and anticipate a rebound, while others say demand is lacking and remain bearish.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

Strong earnings and growing natural-gas demand from AI data centers are driving bullish discussion, alongside Energy Transfers rising distributions. Many investors see its pipeline network as well positioned for that demand, while others are frustrated by muted unit-price action and cite interest rates, energy-market volatility, or the Texas Stock Exchange listing move as potential headwinds.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devons agreed sale of its Eagle Ford assets to Crescent is driving attention, following earlier speculation about asset divestitures and pressure to streamline the company after its Coterra merger. Traders are divided on whether the sale improves focus and capital allocation, with some questioning why the shares have not responded more strongly.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotify shares are drawing attention after its latest quarterly report, with traders focusing on subscriber growth, stronger gross margins and an upbeat profit outlook despite revenue and EPS misses. The sharp gain has surprised some investors, while skeptics point to rising expenses and the earnings shortfall.

3M Co. is a technology company, which engages in manufacturing industrial, safety, and consumer products. It operates through the following segments: Safety and Industrial, Transportation and Electronics, Consumer, and Corporate. The Safety and Industrial segment consists of personal safety, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules. The Transportation and Electronics segment includes electronics, automotive and aerospace, commercial solutions, advanced materials, and transportation safety. The Consumer segment covers consumer healthcare, home care, home improvement, and stationery and office products, such as consumer bandages, braces, supports, respirators, cleaning products, retail abrasives, picture hanging, and consumer air quality solutions. The Corporate segment refers to special items and other corporate expenses. The company was founded by Henry S. Bryan, Hermon W. Cable, John Dwan, William A. McGonagle, and J. Danley Budd in 1902 and is headquartered in St. Paul, MN.

3M Co.

3Ms Q3 earnings beat and higher full-year outlook, alongside an expanded Amazon data-center partnership, are driving discussion. Bulls point to stronger results and growth potential, while skeptical traders argue the Amazon arrangement is conditional and see the post-news rally as overdone.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates

PROKIDNEY CP (PROK) delivered earnings and revenue surprises of -15.39% and -31.82%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates

PROKIDNEY CP (PROK) delivered earnings and revenue surprises of -7.69% and +222.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -15.09% and +2.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of +14.48% and +3.34%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

ProKidney (PROK) to Release Quarterly Earnings on Monday

ProKidney (NASDAQ:PROK) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-prokidney-corp-stock...

ProKidney (NASDAQ:PROK) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded ProKidney from a "strong sell" rating to a "sell" rating in a research report on Saturday...

ProKidney (NASDAQ:PROK) Stock Price Up 9% - Should You Buy?

ProKidney (NASDAQ:PROK) Trading 9% Higher - Here's What Happened...

ProKidney Corp. (NASDAQ:PROK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of ProKidney Corp. (NASDAQ:PROK - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight research firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has issued a...

ProKidney (NASDAQ:PROK) Sees Strong Trading Volume  - Time to Buy?

ProKidney (NASDAQ:PROK) Sees Strong Trading Volume - What's Next...

Hennion & Walsh Asset Management Inc. Has $3.37 Million Holdings in ProKidney Corp. $PROK

Hennion & Walsh Asset Management Inc. lifted its stake in shares of ProKidney Corp. (NASDAQ:PROK - Free Report) by 63.5% in the 4th quarter, according to its most recent Form 13F filing with the...

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.

ProKidney Corp - Ordinary Shares - Class A

ProKidney Stock Skyrockets On Positive Trial Data; Citi Sees 60% Chance Of Success

Equity

Bullish Sentiment

Shares of ProKidney surged more than 500% on Tuesday following upbeat results from its Phase 2 REGEN-007 study and a price target upgrade from Citi.&nbsp;The company is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease (CKD) and diabetes.Citi raised its price target to $9 from $6 and maintained a ‘Buy’ rating, saying the early data “exceeded expectations.”&nbsp;The firm increased the probability of success for the program to 60%, citing statistically significant efficacy seen in Group 1 of the trial, which may support accelerated approval in Phase 3 subject to FDA feedback.The REGEN-007 study showed that kidney function decline was reduced by 78% in group 1 after rilparencel treatment.&nbsp;Patients who received two injections approximately three months apart experienced an improvement in their annual eGFR slope from -5.8 to -1.3 mL/min/1.73 m², representing a statistically and clinically meaningful difference.However, Bank of America was more cautious, reiterating its ‘Underperform’ rating and $1 price target.&nbsp;The firm flagged the absence of a sham comparator, lack of a conference call to discuss the data, and regulatory ambiguity. It stated that the stock’s sharp rally “looks overdone,” especially given that detailed data are likely to be withheld for a future medical meeting.ProKidney reported that no serious side effects were observed in the trial, and the safety results were consistent with earlier studies.&nbsp;Rilparencel already holds RMAT status from the FDA and is also being tested in a larger Phase 3 trial called PROACT 1.&nbsp;The company noted that early signals from REGEN-007 reinforce previously observed efficacy trends in high-risk patient subgroups.On Stocktwits, retail sentiment for <a href="https://stocktwits.com/symbol/PROK">ProKidney</a> was ‘extremely bullish’ amid ‘extremely high’ message volume.One user anticipated strong momentum ahead, saying they were “thinking 100% gain tomorrow.”<stembedurl>https://stocktwits.com/MarketMana/message/620282357</stembedurl>Another poster struck a more cautious but optimistic tone, noting that while they’d “love for this ticker and its well-deserving product [to have] a double-digit run,” biotech stocks often see profit-taking after big moves.&nbsp;They said short sellers could enter soon but saw long-term potential, saying, “If Phase III pans out and it gets FDA approval, it could make you a millionaire.”<stembedurl>https://stocktwits.com/nomendivitiae/message/620278285</stembedurl>ProKidney’s stock has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

The treatment, rilparencel, showed a 78% improvement in kidney function decline in one dosing group, with no serious safety issues reported, supporting its ongoing evaluation in a larger Phase 3 trial.

ProKidney Corp

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.30
Prev Close	$1.47
Open	$1.41
Dividend Yield	0.00%
50-Day Moving Average	$1.67
Beta	2.44
Avg. Volume	1.69M
PE Ratio	-2.34

52-Week High	$3.10
52-Week Low	$1.29
Market Capitalization	$391.51M
EPS (Annual)	-$0.515
Price to Book	-0.30
Revenue Per Employee	$3,865.80

Feed

News

Sentiment

Earnings

Fundamentals

Info

PROK Fundamentals